Announced Thu, 6 Aug · 13:51 IST
Emcure Q1 FY27: Revenue up 22.8%, PAT jumps 36.2% YoY
Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDFExplain this filing
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.6%1-day move
₹1950.00
prior close
₹1938.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-0.4-0.8-0.8+1.6+2.4+2.5+2.8+2.9-3.7————
Up moveDown movePending
AI summary
Consolidated revenue rose 22.8% to Rs 25,804 Mn. EBITDA grew 25.8% to Rs 5,080 Mn with margin at 19.7%, up about 50 bps. PAT surged 36.2% to Rs 2,925 Mn, margin at 11.3%. Domestic business grew 10.2% to Rs 10,953 Mn while international grew 34.2% to Rs 14,851 Mn led by Europe, Canada, and rest of world. Company acquired the remaining 12.05% stake in Gennova making it wholly owned. Gennova sold its mRNA business for Rs 1,395 Mn.
Likely market impact
Strong double-digit growth across revenue, EBITDA, and PAT reflects healthy momentum. Subsidiary consolidation and licensing deals add growth optionality.